IL136462A0 - Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases - Google Patents

Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Info

Publication number
IL136462A0
IL136462A0 IL13646298A IL13646298A IL136462A0 IL 136462 A0 IL136462 A0 IL 136462A0 IL 13646298 A IL13646298 A IL 13646298A IL 13646298 A IL13646298 A IL 13646298A IL 136462 A0 IL136462 A0 IL 136462A0
Authority
IL
Israel
Prior art keywords
combination
proliferative diseases
antineoplastic drugs
treating proliferative
benzocycloheptapyridine
Prior art date
Application number
IL13646298A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL136462(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL136462A0 publication Critical patent/IL136462A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13646298A 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases IL136462A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (1)

Publication Number Publication Date
IL136462A0 true IL136462A0 (en) 2001-06-14

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13646298A IL136462A0 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Country Status (25)

Country Link
EP (1) EP1041985B1 (https=)
JP (1) JP4502503B2 (https=)
KR (1) KR100700907B1 (https=)
CN (1) CN1129431C (https=)
AR (1) AR017440A1 (https=)
AT (1) ATE317697T1 (https=)
AU (1) AU756762B2 (https=)
BR (1) BR9814419A (https=)
CA (1) CA2315693C (https=)
CL (1) CL2007001889A1 (https=)
CO (1) CO5080764A1 (https=)
CZ (1) CZ298511B6 (https=)
DE (1) DE69833509T2 (https=)
DK (1) DK1041985T3 (https=)
ES (1) ES2255196T3 (https=)
HU (1) HUP0102473A3 (https=)
IL (1) IL136462A0 (https=)
MY (1) MY137303A (https=)
NO (1) NO326832B1 (https=)
NZ (1) NZ504928A (https=)
PE (1) PE20000042A1 (https=)
PT (1) PT1041985E (https=)
SK (1) SK285584B6 (https=)
TW (1) TW581763B (https=)
WO (1) WO1999032114A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
CZ20021550A3 (cs) * 1999-11-09 2003-02-12 Societe De Conseils De Recherches Et D'application Produkt zahrnující inhibitor transdukce signálů heterotrimerického G proteinu kombinovaný s jiným protirakovinným činidlem pro terapeutické použití v léčbě rakoviny
WO2001045740A2 (en) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
US20030027808A1 (en) * 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
EP1261343A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
US20030078281A1 (en) * 2000-02-29 2003-04-24 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
EP1267871A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064196A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001244167A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
WO2002056884A2 (en) * 2001-01-22 2002-07-25 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
JP4969016B2 (ja) * 2001-02-15 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
CN1617755A (zh) * 2001-11-30 2005-05-18 先灵公司 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
WO1992011034A1 (en) * 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
IL125062A (en) * 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
CN1304058C (zh) * 1996-03-12 2007-03-14 Pg-Txl有限公司 水溶性紫杉醇产品
EP0959883A4 (en) * 1996-04-03 2001-05-09 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
US20020034725A1 (en) * 1996-04-15 2002-03-21 W. Gillies Mckenna Sensitization of cells to radiation and and chemotherapy
CA2251955A1 (en) * 1996-04-18 1997-10-23 Nancy E. Kohl A method of treating cancer
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
IL131447A0 (en) * 1997-02-18 2001-01-28 Canji Inc Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
CO5080764A1 (es) 2001-09-25
CZ20002236A3 (cs) 2001-04-11
DE69833509D1 (de) 2006-04-20
CN1129431C (zh) 2003-12-03
KR100700907B1 (ko) 2007-03-29
CA2315693C (en) 2010-11-30
JP2001526224A (ja) 2001-12-18
DE69833509T2 (de) 2006-10-26
DK1041985T3 (da) 2006-06-19
PT1041985E (pt) 2006-07-31
HUP0102473A2 (hu) 2002-01-28
ES2255196T3 (es) 2006-06-16
TW581763B (en) 2004-04-01
EP1041985A1 (en) 2000-10-11
JP4502503B2 (ja) 2010-07-14
SK8982000A3 (en) 2001-04-09
NO20003229L (no) 2000-08-22
NZ504928A (en) 2004-12-24
NO326832B1 (no) 2009-02-23
NO20003229D0 (no) 2000-06-21
ATE317697T1 (de) 2006-03-15
EP1041985B1 (en) 2006-02-15
WO1999032114A1 (en) 1999-07-01
CN1284875A (zh) 2001-02-21
MY137303A (en) 2009-01-30
AU756762B2 (en) 2003-01-23
HUP0102473A3 (en) 2003-07-28
AR017440A1 (es) 2001-09-05
AU1907299A (en) 1999-07-12
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
SK285584B6 (sk) 2007-04-05
PE20000042A1 (es) 2000-02-17
CZ298511B6 (cs) 2007-10-24
CL2007001889A1 (es) 2008-01-11
KR20010033452A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
AP9700939A0 (en) Compounds and methods for the treatment of cancer
ZA971937B (en) Combinations for treatment of proliferative diseases.
PL330814A1 (en) Compounds for and methods of delivering pharmaceutical preparations and their application
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
HUP0102473A3 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
GB9812056D0 (en) Pharmaceutical composition for treatment of ibd and rbd
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
IL136515A0 (en) Combination effective for the treatment of impotence
PL344331A1 (en) Combination therapy for treatment of refractory depression
HUP0100012A3 (en) Use for macrolides for the treatment of cancer and macular degeneration
ZA983602B (en) Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination
ZA989556B (en) Benzoxazine derivatives their preparation and their therapeutic application
IL211081A0 (en) Methods and devices for providing prolonged drug therapy
GB9808840D0 (en) Treatment of depression and pharmaceutical preparations therefor
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
HUP0001263A3 (en) Methods of therapeutic administration of anti-cd4ol compounds
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
HUP9904173A3 (en) Pharmaceutical composition for treating viral diseases
GB2344586B (en) Isoquinuclidine derivatives,method of manufacturing the same and therapeutic agents for hypercholesterolemia containing these compounds
SG65766A1 (en) Composition for preventing and treating gingival diseases
AU6126498A (en) Method for the treatment of drug addiction and homeopathic remedy
HK1033259A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases